IMUC - ImmunoCellular Therapeutics Issues Shareholder Letter Providing Update on ICT-107 Program in Newly Diagnosed Glioblastoma Highlights Include ICT-107 Results to Date, Ongoing Data Analyses and Phase III Planning ref. http://finance.yahoo.com/news/immunocellular-therapeutics-issues-shareholder-letter-213800372.html